Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma ...

Jupiter Neurosciences (JUNS) announced it has entered into an agreement with Catalent Pharma Solutions for the production of JOTROL softgel ...

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

The global softgel encapsulation machine market is poised for substantial growth over the next decade, with a projected valuation of USD 178.8 million by 2035. This represents a c ...

Strides Pharma Science in its consolidated financial results for the quarter Q3FY25 ended December 31, 2024 reported revenues of Rs. 1,153.7 crore with a growth 14.6% YoY in Q3FY25. The PAT stood at ...

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

The company posted strong sales growth in 2024, though share-based compensation expenses weighed on its bottom line.

Detailed price information for Nextleaf Solutions Ltd (OILS-CN) from The Globe and Mail including charting and trades.

January 27, 2025. More for You ...

From supplements with magnesium, ashwaganda and more, these are ingredients experts say can help reduce stress and other ...